Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem
Withdrawn
Abiant, Inc.
Phase 4
1969-12-31
This study will compare the interactions of a placebo and two FDA-approved sleeping
medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in
the brain. We want to show that we can use positron emission tomography images to measure the
binding of these medications to the receptors.
Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem
Withdrawn
Sunovion
Phase 4
1969-12-31
This study will compare the interactions of a placebo and two FDA-approved sleeping
medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in
the brain. We want to show that we can use positron emission tomography images to measure the
binding of these medications to the receptors.
Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem
Withdrawn
Kettering Health Network
Phase 4
1969-12-31
This study will compare the interactions of a placebo and two FDA-approved sleeping
medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in
the brain. We want to show that we can use positron emission tomography images to measure the
binding of these medications to the receptors.
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
Withdrawn
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 1/Phase 2
2014-06-01
The purpose of this study is to test feasibility of measuring flumazenil-induced changes in
cortical GABA levels observed with localized 1H-MRS in relation to changes in severity of
hepatic encephalopathy (HE) in subjects with non-alcoholic liver cirrhosis. This study is a
double-blind, placebo-controlled, randomized, cross-over design.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
